Medifocus Inc. Announces Resignation of Chief Financial Officer
August 21 2020 - 5:39PM
Medifocus Inc. (TSXV-MFS) (“
Medifocus” or the
“
Company”) today announced that Mr. Mirsad
Jakubovic has resigned as Chief Financial Officer of the Company.
The Company will commence a search for a new
Chief Financial Officer.
About Medifocus,
Inc.:Medifocus, Inc. (TSX-V: MFS; OTCQB: MDFZF) is a
Biotechnology Company with a portfolio of medical technologies that
utilize patented Focal Thermal Technology to treat conditions
ranging from Prostate Diseases to Breast Cancer. Its Prolieve®
Thermodilatation™ System offers symptomatic relief to men with
Benign Prostatic Hyperplasia (BPH) through a simple, fast,
in-office treatment. Prolieve® is both FDA and Medicare approved
for treating symptomatic BPH with over 100,000 cases performed in
the U.S. alone, and with proven long-term safety, efficacy and
durability. Its APA 1000 Breast Cancer Treatment System was
licensed from Massachusetts Institute of Technology and developed
by the Medifocus team. The Targeted Focal Thermotherapy has been
demonstrated in Phase 2 clinical trials to offer significantly
better tumor shrinkage in patients treated with the combined
Chemothermal therapy compared to those treated with Chemotherapy
alone. APA 1000 was also shown to be effective in reducing margin
positivity among patients treated with such thermotherapy prior to
lumpectomy.
For more details, please
visit:www.medifocusinc.comwww.prolieve.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Investor Relations:Medifocus, Inc.Tel:
410-290-5734
Medifocus (TSXV:MFS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Medifocus (TSXV:MFS)
Historical Stock Chart
From Nov 2023 to Nov 2024